Olmesartan Medoxomil Chlorthalidone Tablet
Description
OLMEROOT-CH
Olmesartan Medoxomil 20 mg and Chlorthalidone 12.5 mg Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Olmesartan Medoxomil IP — 20 mg
Chlorthalidone IP — 12.5 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
OLMEROOT-CH is a scientifically balanced antihypertensive combination of Olmesartan Medoxomil 20 mg and Chlorthalidone 12.5 mg, formulated for the effective management of hypertension and long-term cardiovascular risk reduction. This combination provides dual blood pressure control by combining the renin-angiotensin system blockade of Olmesartan with the long-acting diuretic action of Chlorthalidone, resulting in superior antihypertensive efficacy and enhanced target organ protection.
Olmesartan Medoxomil is a potent angiotensin II receptor blocker (ARB) that promotes vasodilation, reduces peripheral vascular resistance, and provides cardiovascular and renal protection. Chlorthalidone is a long-acting thiazide-like diuretic that increases sodium and water excretion, reduces plasma volume, decreases peripheral vascular resistance, and provides sustained blood pressure control over 24 hours.
OLMEROOT-CH is particularly beneficial in patients with uncontrolled hypertension, hypertension associated with diabetes, chronic kidney disease, obesity, metabolic syndrome, elderly hypertension, and patients requiring intensive combination antihypertensive therapy.
Technical Knowledge of Olmesartan Medoxomil and Chlorthalidone
Olmesartan Medoxomil is a prodrug that is converted to Olmesartan, which selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling.
Chlorthalidone acts primarily on the distal convoluted tubule of the nephron by inhibiting sodium and chloride reabsorption. Compared with Hydrochlorothiazide, Chlorthalidone has a longer half-life and prolonged antihypertensive activity, providing more sustained blood pressure control and improved cardiovascular protection.
The combination of Olmesartan and Chlorthalidone provides complementary antihypertensive mechanisms with additional cardiovascular and renal protective benefits.
Mechanism of Action
Olmesartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, improves vascular function, and protects cardiovascular and renal tissues.
Chlorthalidone promotes sodium and water excretion, reduces plasma volume, decreases peripheral vascular resistance, provides prolonged diuretic activity, and enhances antihypertensive efficacy.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Dual antihypertensive mechanism
Provides sustained 24-hour blood pressure control
Supports cardiovascular and renal protection
Reduces peripheral vascular resistance
Long-acting diuretic support
Improves blood pressure control compared with monotherapy
Suitable for long-term hypertension management under medical supervision
Clinical Applications
OLMEROOT-CH is commonly prescribed for essential hypertension, uncontrolled hypertension requiring combination therapy, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with obesity, metabolic syndrome, elderly hypertension, and long-term cardiovascular risk reduction.
Facts About Olmesartan Medoxomil and Chlorthalidone
Olmesartan is a highly selective ARB with excellent antihypertensive efficacy and proven cardiovascular and renal protective benefits. Chlorthalidone is a long-acting thiazide-like diuretic with extensive clinical evidence demonstrating superior duration of action and significant reduction in cardiovascular events. The combination is widely used for patients requiring intensive blood pressure control and sustained antihypertensive therapy.
Key Facts
ARB and long-acting thiazide-like diuretic combination therapy
Olmesartan Medoxomil 20 mg for vascular and renal protection
Chlorthalidone 12.5 mg for prolonged antihypertensive control
Provides sustained 24-hour blood pressure reduction
Effective in hypertension requiring combination therapy
Evidence-based cardiovascular combination therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
OLMEROOT-CH is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination.
Why Choose OLMEROOT-CH for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Olmesartan Medoxomil 20 mg and Chlorthalidone 12.5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
OLMEROOT-CH from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Olmesartan and Chlorthalidone formulation.
